摘要
目的 从细胞分子水平对胆囊癌化疗的耐药性进行研究 ,为临床化疗药物的筛选提供理论依据并获得更有效的临床化疗效果。方法 应用免疫组织化学的方法 ,检测胆囊癌中的主要耐药基因拓扑异构酶Ⅱα(topoisomeraseⅡα ,TopoⅡα)、P糖蛋白 (P glycoprotein ,P gp)的表达情况 ,并结合病理组织学分级、临床分期进行研究。结果 TopoⅡα在胆囊癌中的表达 ( 91 7% )明显高于对照组 ( 10 % ) (P <0 0 5 )。P糖蛋白在胆囊癌中的表达 ( 5 8 3 % )高于对照组 ( 2 5 % ) (P <0 0 5 )。TopoⅡα在低分化癌的阳性率明显高于中高分化癌 ,但与肿瘤的TNM分期无关。P糖蛋白的表达与胆囊癌组织学分级、TNM分期均无关。结论 TopoⅡα在胆囊癌中明显高表达 ,选择TopoⅡα抑制剂进行化疗有助于提高化疗效果。
Objective To investigate the expression of topoisomerase Ⅱα(Topo Ⅱα) and P-glycoprotein (P-gp) in gallbladder carcinoma.Methods The immunohisto-chemical staining for Topo Ⅱα and P-gp was performed in 36 patients with gallbladder neoplasm and 20 patients with chronic cholecystitis. The correlations between the expression of Topo Ⅱα and P-gp and clinical stage, pathological grade of gallbladder carcinoma were analyzed. Results 91 7% gallbladder carcinoma expressed Topo Ⅱα. The positive rate of Topo Ⅱα was higher in poorly differentiated carcinoma than in well differentiated one (P<0 05). 58 3% gallbladder carcinoma expressed P-gp and the expression was higher than in the control. Conclusions Topo Ⅱα was expressed highly in the gallbladder neoplasm and could be the target of anti-tumor drugs. Selection of the Topo Ⅱα inhibitors should be the key to improve the efficiency of chemotherapy.
出处
《中华肝胆外科杂志》
CAS
CSCD
2001年第3期150-152,共3页
Chinese Journal of Hepatobiliary Surgery
